Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
Ehud Marom, Tel Aviv (IL); and Shai Rubnov, Tel Aviv (IL)
Assigned to Mapi Pharma Ltd., Ness Ziona (IL)
Filed by MAPI PHARMA LTD., Ness Ziona (IL)
Filed on Aug. 24, 2022, as Appl. No. 17/894,447.
Application 17/894,447 is a continuation of application No. 17/213,352, filed on Mar. 26, 2021, granted, now RE49251.
Application 13/408,472 is a continuation in part of application No. 13/258,808, granted, now 8,796,226, issued on Aug. 5, 2014, previously published as PCT/IL2010/000679, filed on Aug. 19, 2010.
Application 17/213,352 is a reissue of application No. 13/408,472, filed on Feb. 29, 2012, granted, now 8,377,885, issued on Feb. 19, 2013.
Application 17/894,447 is a reissue of application No. 13/408,472, filed on Feb. 29, 2012, granted, now 8,377,885, issued on Feb. 19, 2013.
Claims priority of provisional application 61/291,928, filed on Jan. 4, 2010.
[ 30. A method of treating multiple sclerosis comprising the step of parenterally administering to a subject in need thereof a long acting pharmaceutical composition comprising a therapeutically effective amount of a pharmaceutically acceptable salt of glatiramer, and a pharmaceutically acceptable biodegradable or non-biodegradable carrier which provides the composition in a sustained release depot form which releases a therapeutically effective amount of the pharmaceutically acceptable salt of glatiramer over a period of one week to 6 months, wherein the pharmaceutically acceptable salt of glatiramer is glatiramer acetate, the depot form contains between 20 mg and 750 mg of glatiramer acetate and the carrier comprises a poly (D,L-lactide-co-glycolide) (PLGA). ]